Kidney Transplant Clinical Trials
Here are the 6 most popular medical studies for kidney transplant
Prebiotic
Prebiotic Therapy for Kidney Transplant Outcomes
This trial is testing whether a prebiotic called human milk oligosaccharide (HMO) can improve kidney transplant outcomes by reducing delayed graft function and side effects from post transplant therapy.
Monoclonal Antibodies
Clazakizumab for Kidney Transplant Rejection
This trial is testing a new drug to treat people with antibody mediated rejection, which is a serious form of allograft rejection. Clazakizumab, an anti-IL6 monoclonal antibody, will be given monthly for six to twelve doses, and patients will have biopsies at 6 and 12 months to check for improvement.
Bone Marrow Aspiration for Kidney Transplant Rejection
This trial is testing whether two different tests can show why patients who have had a kidney transplant and have developed antibodies against their donor are at a greater risk for their transplanted organ being rejected.
BB3 for Delayed Graft Function
The objective of the study is to evaluate the safety and activity of a investigational drug in improving renal function in patients who have undergone renal transplantation and have signs and symptoms of significant renal injury and are at risk for dialysis.
Popular filter options for kidney transplant trials
Chronic Kidney Disease Clinical Trials
View 21 Chronic Kidney Disease medical studies.
Monoclonal Antibodies
REGN5459 + REGN5458 for Transplant-Ready Chronic Kidney Disease
This trial is testing two drugs, REGN5459 and REGN5458, to see if they are safe and tolerable for patients with chronic kidney disease who need a kidney transplant and are highly sensitized to human leukocyte antigen. The secondary objectives are to determine the drug's effect on reducing levels of anti-HLA alloantibodies, on the duration of this effect, and on other immunological measures.
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplant Desensitization
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Behavioral Intervention
mHealth Messaging Intervention Group for Kidney Failure
"This trial aims to see if a mobile technology intervention can help young people who have had kidney or liver transplants to remember to take their medication on time. The intervention includes an electronic pillbox and text
Stem Cell Therapy
Stem Cell Infusion for Kidney Transplant Tolerance
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Monoclonal Antibodies
TOL101 +1 More for Kidney Failure
Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response. In general, induction therapy is associated with better outcomes compared to the absence of induction therapy. However, currently used induction agents, some of which are not labeled or indicated for induction therapy in transplantation, have drawbacks related to long-term immune system suppression increasing susceptibility to opportunistic infections or malignancies, and other immune-mediated side effects. An unmet medical need exists for a more specific approach to prevent acute organ rejection, without unnecessarily exposing the patient to non-specific or open-ended immune suppression, which may exacerbate the risks of infections and malignancies. TOL101 is a novel antibody that targets a very specific immune cell type that is critical in the acute organ rejection response. In this two-part study, TOL101 will be evaluated for the prophylaxis of acute organ rejection when used as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus in first time kidney transplant recipients. This study will test the hypothesis that a more specific approach (with TOL101) to prevention of acute organ rejection may provide similar or better efficacy than the currently used induction antibodies (such as Anti-Thymocyte Globulin or Thymoglobulin) while carrying fewer risks in terms of opportunistic infections, malignancies and adverse effects.
Chronic Kidney Failure Clinical Trials
View 19 Chronic Kidney Failure medical studies.
Monoclonal Antibodies
REGN5459 + REGN5458 for Transplant-Ready Chronic Kidney Disease
This trial is testing two drugs, REGN5459 and REGN5458, to see if they are safe and tolerable for patients with chronic kidney disease who need a kidney transplant and are highly sensitized to human leukocyte antigen. The secondary objectives are to determine the drug's effect on reducing levels of anti-HLA alloantibodies, on the duration of this effect, and on other immunological measures.
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplant Desensitization
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Behavioral Intervention
mHealth Messaging Intervention Group for Kidney Failure
"This trial aims to see if a mobile technology intervention can help young people who have had kidney or liver transplants to remember to take their medication on time. The intervention includes an electronic pillbox and text
Monoclonal Antibodies
TOL101 +1 More for Kidney Failure
Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response. In general, induction therapy is associated with better outcomes compared to the absence of induction therapy. However, currently used induction agents, some of which are not labeled or indicated for induction therapy in transplantation, have drawbacks related to long-term immune system suppression increasing susceptibility to opportunistic infections or malignancies, and other immune-mediated side effects. An unmet medical need exists for a more specific approach to prevent acute organ rejection, without unnecessarily exposing the patient to non-specific or open-ended immune suppression, which may exacerbate the risks of infections and malignancies. TOL101 is a novel antibody that targets a very specific immune cell type that is critical in the acute organ rejection response. In this two-part study, TOL101 will be evaluated for the prophylaxis of acute organ rejection when used as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus in first time kidney transplant recipients. This study will test the hypothesis that a more specific approach (with TOL101) to prevention of acute organ rejection may provide similar or better efficacy than the currently used induction antibodies (such as Anti-Thymocyte Globulin or Thymoglobulin) while carrying fewer risks in terms of opportunistic infections, malignancies and adverse effects.
Phase 3 Kidney Transplant Clinical Trials
View 99 phase 3 kidney transplant medical studies.
Virus Therapy
Janssen COVID-19 Vaccine Booster for Kidney Transplant Recipients
This trial is testing if one dose of the Janssen vaccine can provide enough immunity for people who have had kidney transplants and have already received two or three doses of another vaccine.
Behavioral Intervention
SystemCHANGE for Kidney Disease
With kidney transplant (KT) recipients as our exemplar population, our goal is to develop and test interventions that increase medication adherence (MA) in chronically ill adults. Among adult KT recipients, non-adherence to immunosuppressive medications (MNA) is the leading predictor of poor outcomes, including rejection, kidney loss, and death. An alarming one-third of KT patients experience MNA even though the problem is preventable. Adherence intervention studies have proven marginally effective for those with acute and chronic illnesses and ineffective for adult KT recipients. Using a randomized controlled trial design with an attention-control group, this R01 will test an innovative 6-month SystemCHANGE intervention to enhance immunosuppressive MA in adult non-adherent KT recipients. This intervention shows great promise for increasing MA with a large effect size of 1.4 in our pilot study. Grounded in the socio-ecological model, SystemCHANGE seeks to systematically improve MA behaviors by identifying and shaping routines, involving supportive others in routines, and using medication taking feedback through small patient-lead experiments to change and maintain behavior. The Medication Event Monitoring System cap, which contains microelectronics that record the date and time of the cap removal, will be used to measure MA. Persistence of the MA behavior change will be examined by evaluating the difference in MA between the two groups during the 6-month maintenance phase. Mediators and moderators of MA will be examined. Health outcomes will be compared and a cost-effectiveness analysis will be conducted.
Kidney Transplant Clinical Trials With No Placebo
View 99 kidney transplant medical studies that do not have a placebo group.
Virus Therapy
Janssen COVID-19 Vaccine Booster for Kidney Transplant Recipients
This trial is testing if one dose of the Janssen vaccine can provide enough immunity for people who have had kidney transplants and have already received two or three doses of another vaccine.
Monoclonal Antibodies
REGN5459 + REGN5458 for Transplant-Ready Chronic Kidney Disease
This trial is testing two drugs, REGN5459 and REGN5458, to see if they are safe and tolerable for patients with chronic kidney disease who need a kidney transplant and are highly sensitized to human leukocyte antigen. The secondary objectives are to determine the drug's effect on reducing levels of anti-HLA alloantibodies, on the duration of this effect, and on other immunological measures.
Calcineurin Inhibitor
Extended vs Immediate Release Tacrolimus for Kidney Transplant Rejection
This trial will compare outcomes of kidney transplant patients taking Envarsus XR versus tacrolimus. Outcomes include rejection rates, HLA antibodies, kidney function, and cell-free DNA levels.
Calcineurin Inhibitor
Once-Daily vs Twice-Daily Tacrolimus for Kidney Transplant Recipients
This trial is testing whether a once-daily tacrolimus pill causes fewer side effects and is more convenient than the twice-daily tacrolimus pill, and whether patients' quality of life is better on the once-daily pill.
Hematopoietic Stem Cell Transplantation
Stem Cell + Treg Therapy for Kidney Transplant
This trial will test whether a combination of radiation and drugs followed by infusion of donor cells will allow recipients to eventually stop taking anti-rejection drugs after receiving a kidney from a living donor.
View More Kidney Transplant Trials
See another 73 medical studies focused on kidney transplant.
Frequently Asked Questions
Introduction to kidney transplant
What are the top hospitals conducting kidney transplant research?
When it comes to cutting-edge clinical trials in the field of kidney transplant, several hospitals are leading the way. In Rochester, Minnesota, Mayo Clinic is at the forefront with six active kidney transplant trials. With its extensive expertise and state-of-the-art facilities, Mayo Clinic continues to push boundaries in this specialized area of medicine. Meanwhile, on the West Coast in Los Angeles, Cedars-Sinai Medical Center is also making significant contributions with four ongoing kidney transplant trials. This renowned institution has a long-standing reputation for excellence and innovation in healthcare. Further south in Charleston, South carolina, the Medical University of South Carolina is actively involved in four kidney transplant trials as well—showcasing their commitment to advancing transplantation techniques and improving patient outcomes.
Heading back north to Chicago brings us to the University of Illinois at Chicago—a hub for medical research and discovery. Here they have three active kidney transplant clinical trials underway that aim to explore novel treatment approaches and enhance post-transplant care protocols. Lastly but certainly not least—in sunny San Diego—the California Institute of Renal Research joins this esteemed group with three ongoing kidney transplant trials offering hope for patients awaiting life-changing transplants.
While these hospitals may not have conducted any previous specific clinical studies focused solely on kidney transplants according to available records; their current endeavors demonstrate a shared dedication towards advancing knowledge and refining methods surrounding this life-saving procedure. As we look toward the future of organ transplantation research, these institutions continue pushing boundaries as pioneers within their respective regions - bringing together experts from various disciplines who relentlessly work towards improving quality of life for those affected by renal failure
Which are the best cities for kidney transplant clinical trials?
In the realm of kidney transplant clinical trials, several cities emerge as frontrunners for cutting-edge research. Los Angeles, California leads the way with 15 active trials investigating treatments like Clazakizumab, Nested RCT - Treatment Group (Abatacept), and Anti-BK polyomavirus (AntiBKV). Chicago, Illinois closely follows with 13 ongoing studies focusing on interventions such as Clazakizumab, HIV D+/R+, and REGN5459. Additionally, New york City in New York and Philadelphia in Pennsylvania each host 11 active trials exploring similar avenues of treatment. Finally, Baltimore in Maryland rounds out the list with 10 ongoing trials centered around promising approaches like HIV D+/R+ and Clazakizumab. These cities serve as beacons of hope for individuals seeking access to advanced kidney transplant clinical trials that may revolutionize care options and improve outcomes.
Which are the top treatments for kidney transplant being explored in clinical trials?
Kidney transplant research is constantly evolving, and clinical trials are focusing on innovative treatments to improve outcomes. Currently, the top treatments being explored in clinical trials include:
- Belatacept: 8 active kidney transplant trials, 85 all-time kidney transplant trials
- Eculizumab: 6 active kidney transplant trials, 68 all-time kidney transplant trials
What are the most recent clinical trials for kidney transplant?
Exciting advancements in kidney transplant research are underway, offering new hope for patients in need. One such trial is exploring the potential of dapagliflozin—a medication typically used to treat diabetes—in improving outcomes after kidney transplantation. Additionally, researchers are investigating an innovative approach aimed at enhancing immune tolerance among mismatched kidney transplant recipients. Another study focuses on the use of abatacept as a treatment option for these individuals. With ongoing efforts and rigorous trials, the field of kidney transplantation continues to evolve, bringing us closer to improved patient care and better long-term outcomes.
What kidney transplant clinical trials were recently completed?
Recently, several clinical trials focused on kidney transplant have achieved their objectives, bringing hope for improved treatments. Notably, a trial investigating the efficacy of Uproleselan in preventing kidney transplant rejection was completed in October 2021. Additionally, a study evaluating the use of mRNA-1273 as an innovative therapy for post-transplant complications reached its conclusion in September 2021. These advancements highlight the dedication of researchers and offer potential avenues to enhance outcomes for individuals undergoing kidney transplantation.